---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-038498"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:03:58.924838+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical Q1 revenue down $13k; enrolls 10 in pivotal CI trial; secures $10M funding

## Summary
- Net revenues decreased $13k YoY to an undisclosed amount; cash balance $5.3M as of March 31, 2025.
- R&D expenses rose $400k YoY due to headcount and clinical study startup for Acclaim cochlear implant.
- Enrolled 10 participants in first stage of pivotal clinical trial for fully implanted Acclaim CI; 6 activated.
- Secured additional $10M in funding to advance pivotal clinical trial; no serious adverse events reported.
- Modifications appear to address electrical system noise observed in earlier feasibility study.

## SEC filing metadata
- accession: 0001213900-25-038498
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/0001213900-25-038498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390025038498/ea0240479-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-038498
- JSON: https://secwatch.observer/filing/0001213900-25-038498.json
- Plain text: https://secwatch.observer/filing/0001213900-25-038498.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.